Patient-Derived Xenograft/PDX Model Market
Patient-Derived Xenograft/PDX Model Market Size, Share & Trends Analysis Report By Type (Mice Model, and Rat Model) By Tumor Models (Gynecological, Gastrointestinal, Respiratory Tumor Model and Others) By Application (Preclinical drug development, Biomarker analysis, and Basic Cancer Research) By End-User (Pharmaceutical & Biotechnology Companies, CROs, and Academic & Research Institutions), Forecast Period (2026-2035)
Industry Overview
Patient-derived xenograft/PDX model market is expected to reach approximately $1,330.5 million by 2035, growing at a CAGR of 11.6% from 2026 to 2035, up from $445.6 million in 2025. The growth of the global patient-derived xenograft (PDX) model market is primarily driven by the increasing demand for more predictive preclinical models in oncology research. Rising investment in targeted cancer therapies and immuno-oncology has amplified the need for accurate models that closely mimic human tumor biology. Additionally, the expansion of contract research organizations and academic collaborations has facilitated broader adoption of PDX models for drug efficacy and biomarker studies. Advances in genetic engineering and humanized mouse models have further enhanced the reliability and applicability of these models. Moreover, the growing emphasis on personalized medicine and translational research has reinforced the role of PDX models in bridging laboratory findings with clinical outcomes.
Market Dynamics
Expansion of Humanized and Immuno-Oncology PDX Models
The development of humanized and immuno-oncology patient-derived xenograft (PDX) models is emerging as a key trend in the market. These models allow for more accurate evaluation of immunotherapies by replicating human immune responses within tumor microenvironments. Increased adoption by pharmaceutical and biotechnology companies for preclinical testing is driving demand. Furthermore, advancements in genetic engineering have enabled the creation of more representative tumor models for diverse cancer types. Academic and research institutions are also leveraging these models for translational studies.
Integration of PDX Models with Biomarker and Genomic Research
The integration of PDX models with biomarker analysis and genomic profiling is another significant trend shaping the market. This approach allows researchers to identify predictive biomarkers and assess treatment responses more precisely. The combination of PDX platforms with high-throughput sequencing and molecular characterization tools is facilitating targeted therapy development. Pharmaceutical companies increasingly rely on this integration to improve clinical trial success rates and reduce drug development timelines. Additionally, it supports the growing focus on precision medicine by linking tumor genetics with therapeutic efficacy.
Market Segmentation
- Based on the type, the market is segmented into the mice model and the rat model.
- Based on the tumor models, the market is segmented into the gynecological tumor model, gastrointestinal tumor model, respiratory tumor model and others.
- Based on the application, the market is segmented into preclinical drug development, biomarker analysis and basic cancer research.
- Based on the end-user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs) and academic & research institutions.
Gastrointestinal Tumor Model to Lead the Market with the Largest Share
The growth of the global patient?derived xenograft market is significantly influenced by the increasing focus on gastrointestinal tumor research. Rising prevalence of colorectal, gastric, and pancreatic cancers has led to greater demand for models that accurately replicate human tumor biology. Pharmaceutical and biotechnology companies are increasingly adopting gastrointestinal PDX models for evaluating drug efficacy and safety in preclinical studies. Additionally, these models enable detailed investigation of tumor heterogeneity and molecular pathways, supporting precision medicine initiatives. Academic and research institutions are also leveraging these models to explore novel therapeutic targets.
Preclinical Drug Development: A Key Segment in Market Growth
The expansion of the global patient?derived xenograft model market is largely driven by the increasing reliance on preclinical drug development in oncology research. PDX models provide a reliable platform for assessing the efficacy and safety of novel therapeutics before clinical trials. Pharmaceutical and biotechnology companies are utilizing these models to better predict human responses and optimize drug candidates. The ability of PDX models to mimic patient-specific tumor biology enhances translational research and reduces the risk of clinical trial failures. Furthermore, these models support the evaluation of combination therapies and targeted treatments.
Regional Outlook
The global patient?derived xenograft market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Rising Oncology Research and Translational Studies in Asia-Pacific
The growth of the patient?derived xenograft model market in Asia-Pacific is being driven by increasing investment in oncology research and translational studies. Strong collaboration between pharmaceutical companies and academic institutions has expanded the adoption of PDX models for preclinical testing. Advances in molecular profiling and humanized mouse models are enhancing the accuracy and relevance of these studies. Regulatory support and government initiatives for precision medicine are also encouraging broader use of PDX platforms. Additionally, rising demand for targeted cancer therapies has reinforced the importance of clinically representative tumor models.
North America Region Dominates the Market with Major Share
The North American patient?derived xenograft model market is expanding due to the strong presence of pharmaceutical and biotechnology companies investing heavily in oncology drug development. High adoption of advanced preclinical models enables more accurate evaluation of therapeutic efficacy and safety. Research institutions in the region are increasingly utilizing PDX models for biomarker discovery and translational studies. Additionally, the availability of well-established contract research organizations (CROs) facilitates broader access to these models. Rising investment in precision medicine and immuno-oncology further drives market demand.
Market Players Outlook
The major companies operating in the global patient?derived xenograft model market include Abnova Corp., Champions Oncology, Inc., Charles River Laboratories International, Inc., Inotiv, Inc. and WuXi AppTec Co., Ltd., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In April 2025, Charles River Laboratories International, Inc. announced the development of PDX-derived tumoroids (3D cultures) that aim to improve the translatability of in vivo results and provide more predictive drug testing alternatives.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global patient?derived xenograft model market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Patient-Derived Xenograft Market Sales Analysis – Type| Tumor Models| Application| End-User|($ Million)
- Patient-Derived Xenograft Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Patient-Derived Xenograft Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Patient-Derived Xenograft Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Patient-Derived Xenograft Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Patient-Derived Xenograft Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Patient-Derived Xenograft Market Revenue and Share by Manufacturers
- Patient-Derived Xenograft Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Abnova Corp.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Champions Oncology, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Charles River Laboratories International, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Inotiv, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- WuXi AppTec Co., Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Abnova Corp.
- Key Company Analysis
- Global Patient-Derived Xenograft Market Sales Analysis by Type ($ Million)
- Mice Model
- Rat Model
- Global Patient-Derived Xenograft Market Sales Analysis by Tumor Models ($ Million)
- Gynecological Tumor Model
- Gastrointestinal Tumor Model
- Respiratory Tumor Model
- Others
- Global Patient-Derived Xenograft Market Sales Analysis by Application ($ Million)
- Preclinical Drug Development
- Biomarker Analysis
- Basic Cancer Research
- Global Patient-Derived Xenograft Market Sales Analysis by End-User ($ Million)
- Pharmaceutical & Biotechnology Companies
- Contract research organizations (CROs)
- Academic & Research Institutions
- Regional Analysis
- North American Patient-Derived Xenograft Market Sales Analysis – Type| Tumor Models| Application| End-User |Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Patient-Derived Xenograft Market Sales Analysis – Type| Tumor Models| Application| End-User| Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Patient-Derived Xenograft Market Sales Analysis – Type| Tumor Models| Application| End-User| Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Patient-Derived Xenograft Market Sales Analysis – Type| Tumor Models| Application | End-User |Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abnova Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Altogen Labs
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aragen Life Sciences Pvt. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BioDuro-Sundia International
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Champions Oncology, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Charles River Laboratories International, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Crown Bioscience, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- EPO Berlin-Buch GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GemPharmatech Co. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Genesis Biotechnology Group
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hera BioLabs, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Inotiv, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Living Tumor Laboratory
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Oncodesign Services
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shanghai LIDE Biotech Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- The Jackson Laboratory
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Urosphere SAS
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- WuXi AppTec Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- XenTech SAS
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abnova Corp.
1. Global Patient-Derived Xenograft Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Patient-Derived Xenograft Mice Model Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Patient-Derived Xenograft Rat Model Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Patient-Derived Xenograft Market Research and Analysis by Tumor Models, 2025–2035 ($ Million)
5. Global Gynecological Tumor Patient-Derived Xenograft Model Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Gastrointestinal Tumor Patient-Derived Xenograft Model Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Respiratory Tumor Patient-Derived Xenograft Model Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Others Tumor Patient-Derived Xenograft Model Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Patient-Derived Xenograft Market Research and Analysis by Application, 2025–2035 ($ Million)
10. Global Patient-Derived Xenograft In Preclinical Drug Development Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Patient-Derived Xenograft In Biomarker Analysis Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Patient-Derived Xenograft In Basic Cancer Research Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Patient-Derived Xenograft Market Research and Analysis by End-User, 2025–2035 ($ Million)
14. Global Patient-Derived Xenograft For Pharmaceutical & Biotechnology Companies Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Patient-Derived Xenograft For Contract Research Organizations (CROs) Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Patient-Derived Xenograft For Academic & Research Institutions Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Patient-Derived Xenograft Market Research and Analysis by Region, 2025–2035 ($ Million)
18. North American Patient-Derived Xenograft Market Research and Analysis by Country, 2025–2035 ($ Million)
19. North American Patient-Derived Xenograft Market Research and Analysis by Type, 2025–2035 ($ Million)
20. North American Patient-Derived Xenograft Market Research and Analysis by Tumor Models, 2025–2035 ($ Million)
21. North American Patient-Derived Xenograft Market Research and Analysis by Application, 2025–2035 ($ Million)
22. North American Patient-Derived Xenograft Market Research and Analysis by End-User, 2025–2035 ($ Million)
23. European Patient-Derived Xenograft Market Research and Analysis by Country, 2025–2035 ($ Million)
24. European Patient-Derived Xenograft Market Research and Analysis by Type, 2025–2035 ($ Million)
25. European Patient-Derived Xenograft Market Research and Analysis by Tumor Models, 2025–2035 ($ Million)
26. European Patient-Derived Xenograft Market Research and Analysis by Application, 2025–2035 ($ Million)
27. European Patient-Derived Xenograft Market Research and Analysis by End-User, 2025–2035 ($ Million)
28. Asia-Pacific Patient-Derived Xenograft Market Research and Analysis by Country, 2025–2035 ($ Million)
29. Asia-Pacific Patient-Derived Xenograft Market Research and Analysis by Type, 2025–2035 ($ Million)
30. Asia-Pacific Patient-Derived Xenograft Market Research and Analysis by Tumor Models, 2025–2035 ($ Million)
31. Asia-Pacific Patient-Derived Xenograft Market Research and Analysis by Application, 2025–2035 ($ Million)
32. Asia-Pacific Patient-Derived Xenograft Market Research and Analysis by End-User, 2025–2035 ($ Million
33. Rest of the World Patient-Derived Xenograft Market Research and Analysis by Region, 2025–2035 ($ Million)
34. Rest of the World Patient-Derived Xenograft Market Research and Analysis by Type, 2025–2035 ($ Million)
35. Rest of the World Patient-Derived Xenograft Market Research and Analysis by Tumor Models, 2025–2035 ($ Million)
36. Rest of the World Patient-Derived Xenograft Market Research and Analysis by Application, 2025–2035 ($ Million)
37. Rest of the World Patient-Derived Xenograft Market Research and Analysis by End-User, 2025–2035 ($ Million)
1. Global Patient-Derived Xenograft Market Share by Type, 2025 Vs 2035 (%)
2. Global Patient-Derived Xenograft Mice Model Market Share by Region, 2025 Vs 2035 (%)
3. Global Patient-Derived Xenograft Rat Model Market Share by Region, 2025 Vs 2035 (%)
4. Global Patient-Derived Xenograft Market Share by Tumor Models, 2025 Vs 2035 (%)
5. Global Gynecological Tumor Patient-Derived Xenograft Model Market Share by Region, 2025 Vs 2035 (%)
6. Global Gastrointestinal Tumor Patient-Derived Xenograft Model Market Share by Region, 2025 Vs 2035 (%)
7. Global Respiratory Tumor Patient-Derived Xenograft Model Market Share by Region, 2025 Vs 2035 (%)
8. Global Others Tumor Patient-Derived Xenograft Model Market Share by Region, 2025 Vs 2035 (%)
9. Global Patient-Derived Xenograft Market Share by Application, 2025 Vs 2035 (%)
10. Global Patient-Derived Xenograft In Preclinical Drug Development Market Share by Region, 2025 Vs 2035 (%)
11. Global Patient-Derived Xenograft In Biomarker Analysis Market Share by Region, 2025 Vs 2035 (%)
12. Global Patient-Derived Xenograft In Basic Cancer Research Market Share by Region, 2025 Vs 2035 (%)
13. Global Patient-Derived Xenograft Market Share by End-User, 2025 Vs 2035 (%)
14. Global Patient-Derived Xenograft For Pharmaceutical & Biotechnology Companies Market Share by Region, 2025 Vs 2035 (%)
15. Global Patient-Derived Xenograft For Contract Research Organizations (CROs) Market Share by Region, 2025 Vs 2035 (%)
16. Global Patient-Derived Xenograft For Academic & Research Institutions Market Share by Region, 2025 Vs 2035 (%)
17. Global Patient-Derived Xenograft Market Research and Analysis by Region, 2025–2035 ($ Million)
18. US Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
19. Canada Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
20. UK Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
21. France Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
22. Germany Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
23. Italy Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
24. Spain Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
25. Russia Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
26. Rest of Europe Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
27. India Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
28. China Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
29. Japan Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
30. South Korea Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
31. Australia and New Zealand Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
32. ASEAN Economies Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
33. Rest of Asia-Pacific Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
34. Latin America Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
35. Middle East and Africa Patient-Derived Xenograft Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Patient-Derived Xenograft/PDX Model Market in 2025 is estimated to be around $445.6 Million.
North America holds the largest share in the Patient-Derived Xenograft/PDX Model Market.
Leading players in the Patient-Derived Xenograft/PDX Model Market include Abnova Corp., Champions Oncology, Inc., Charles River Laboratories International, Inc., Inotiv, Inc. and WuXi AppTec Co., Ltd., among others.
Patient-Derived Xenograft/PDX Model Market is expected to grow at a CAGR of 11.6% from 2026 to 2035.
The Patient-Derived Xenograft (PDX) Model Market is growing due to increasing demand for personalized cancer therapies, rising oncology research activities, advancements in precision medicine, and higher investment in drug discovery and preclinical testin
